OncoMyx Therapeutics was co-founded by ASU's Grant McFadden and will use the series A funding to advance the development of its lead asset aimed at several indications of cancer.

OncoMyx Therapeutics, a US-based cancer immunotherapy spinout of Arizona State University (ASU), yesterday closed a $25m series A round co-led by Boehringer Ingelheim Venture Fund (BIVF), the corporate venturing vehicle of pharmaceutical firm Boehringer Ingelheim.
BIVF co-led the round with private equity firm Delos Capital and investment vehicle Xeraya Capital, while Korea Investment Partners, City Hill Ventures and Madison Partners also participated.
Founded in 2018, OncoMyx Therapeutics aims to exploit an oncolytic agent –  a virus that selectively…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?